FLUMATINIB MESYLATE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C29H29F3N8O.CH4O3S
Molecular Weight	658.694
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS(O)(=O)=O.CN1CCN(CC2=CC=C(C=C2C(F)(F)F)C(=O)NC3=CC(NC4=NC=CC(=N4)C5=CC=CN=C5)=C(C)N=C3)CC1

InChI

InChIKey=ZSASDYCFROUKTJ-UHFFFAOYSA-N

InChI=1S/C29H29F3N8O.CH4O3S/c1-19-26(38-28-34-9-7-25(37-28)21-4-3-8-33-16-21)15-23(17-35-19)36-27(41)20-5-6-22(24(14-20)29(30,31)32)18-40-12-10-39(2)11-13-40;1-5(2,3)4/h3-9,14-17H,10-13,18H2,1-2H3,(H,36,41)(H,34,37,38);1H3,(H,2,3,4)

HIDE SMILES / InChI

Molecular Formula	CH4O3S
Molecular Weight	96.106
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C29H29F3N8O
Molecular Weight	562.5888
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20703259
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/20478851 | http://adisinsight.springer.com/drugs/800035564

Flumatinib (HHGV678) is an orally bioavailable antineoplastic tyrosine kinase inhibitor. Flumatinib inhibits the wild-type forms of Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and mast/stem cell growth factor receptor (SCFR; c-Kit) and forms of these proteins with certain point mutations. Flumatinib was extensively metabolized after oral administration, and the major metabolic pathways observed were amide hydrolysis, demethylation, oxidation, and glucuronide conjugation. It is in phase III clinical trials for the treatment of Chronic myeloid leukemia (in China).

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Tyrosine-protein kinase ABL 29 Target ID: CHEMBL1862 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20703259	Inhibitor 8297	1.2 nM [IC50]
Platelet-derived growth factor receptor beta 56 Target ID: CHEMBL1913 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20703259	Inhibitor 8297	308.0 nM [IC50]
Stem cell growth factor receptor 53 Target ID: CHEMBL1936 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20703259	Inhibitor 8297	665.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic myeloid leukemia 25 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20478851 http://adisinsight.springer.com/drugs/800035564	Primary		Phase III 656	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance.	2010 Oct	20703259
[Effect of flumatinib mesylate on C-MYC, HIF-1α and VEGF in U226 line].	2013 Dec	24370036
Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.	2014 Jan	24205792

Patents

Sample Use Guides

In Vivo Use Guide

400 mg once daily or 600 mg once daily

Route of Administration: Oral

In Vitro Use Guide

Flumatinib of 10.0 micromol/L induced cell apoptosis of 40.06% and 33.32% in K562R and 32Dp210(T315I) cell lines

Substance Class	Chemical Created by `admin` on `Sat Dec 16 05:32:52 GMT 2023` Edited by `admin` on `Sat Dec 16 05:32:52 GMT 2023`
Record UNII	95Y8L63NBC
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FLUMATINIB MESYLATE

Common Name

English

Flumatinib mesylate [WHO-DD]

Common Name

English

BENZAMIDE, 4-((4-METHYL-1-PIPERAZINYL)METHYL)-N-(6-METHYL-5-((4-(3-PYRIDINYL)-2-PYRIMIDINYL)AMINO)-3-PYRIDINYL)-3-(TRIFLUOROMETHYL)-, MONOMETHANESULFONATE

Systematic Name

English

BENZAMIDE, 4-((4-METHYL-1-PIPERAZINYL)METHYL)-N-(6-METHYL-5-((4-(3-PYRIDINYL)-2-PYRIMIDINYL)AMINO)-3-PYRIDINYL)-3-(TRIFLUOROMETHYL)-, METHANESULFONATE (1:1)

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C129825